Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | WTX-330 |
Synonyms | |
Therapy Description |
WTX-330 comprises IL-12 linked to an antibody blockade domain and a half-life extension domain by linkers that can be cleaved by proteases in the tumor microenvironment, which potentially enhances antitumor immune response and reduces tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr 2055). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
WTX-330 | WTX 330|WTX330 | WTX-330 comprises IL-12 linked to an antibody blockade domain and a half-life extension domain by linkers that can be cleaved by proteases in the tumor microenvironment, which potentially enhances antitumor immune response and reduces tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr 2055). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05678998 | Phase I | WTX-330 | WTX-330 in Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma | Recruiting | USA | 0 |